TF
Therapeutic Areas
Omeros Corporation Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OMIDRIA | Prevention of intraoperative miosis & postoperative pain in cataract surgery | Approved |
| Narsoplimab (OMS721) | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) | Submitted |
| OMS906 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 |
| OMS527 | Addiction disorders (e.g., cocaine, methamphetamine) | Preclinical/Phase 1 |
Leadership Team at Omeros Corporation
GA
Gregory A. Demopulos, M.D.
Chairman and Chief Executive Officer
MA
Michael A. Jacobsen
Chief Financial Officer
ML
Michael L. D. Abernathy
Senior Vice President, General Counsel, and Corporate Secretary
PA
Peter A. Senter, Ph.D.
Senior Vice President and Chief Scientific Officer
TJ
Thomas J. Cable
Senior Vice President, Commercial Operations and Business Development
MD
Michael D. Smith
Senior Vice President, Technical Operations
SP
Steven P. James
Senior Vice President, Corporate Development
MR
Michael R. Chastain, Ph.D.
Vice President, Regulatory Affairs
MH
Michael H. Davidson, M.D.
Board Member (Lead Independent Director)
JS
Jean-Pierre Sommadossi, Ph.D.
Board Member